Verona Pharma plc (I9SA) — Long-term Investment Intensity

Latest as of June 2025: 2.6%

Verona Pharma plc (I9SA) has a Long-term Investment Intensity of 2.6% as of June 2025. Long-term investments of €15.00 Million represent 2.6% of total assets of €572.87 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See I9SA total equity for net asset value and shareholders' equity analysis.

LT Investment Intensity

2.6%
LT Investments / Total Assets

Long-term Investments

€15.00 Million
EUR

Total Assets

€572.87 Million
EUR

Country

Germany
F

Verona Pharma plc Long-term Investment Intensity (2021–2024)

This chart shows how Verona Pharma plc's Long-term Investment Intensity has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the intensity stands at 2.6%, reflecting long-term investments of €15.00 Million against total assets of €572.87 Million EUR. Also explore Verona Pharma plc (I9SA) total assets for the complete picture of this company's asset base.

Annual Long-term Investment Intensity for Verona Pharma plc (2021–2024)

The table below presents the year-by-year Long-term Investment Intensity for Verona Pharma plc from 2021 to 2024, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see I9SA market cap.

Year LT Investment Intensity LT Investments (EUR) Total Assets Change (pp)
2024 3.2% €15.00 Million €474.24 Million ▼ -1.7 pp
2023 4.9% €15.00 Million €308.12 Million ▼ -0.9 pp
2022 5.8% €15.00 Million €259.47 Million ▼ -2.3 pp
2021 8.0% €15.00 Million €186.59 Million
pp = percentage points